文献速递心脑血管急症

银杏二萜内酯葡胺治疗急性缺血性卒中:一项随机临床试验

Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2023-08-01
一句话结论在急性缺血性卒中患者中,银杏二萜内酯葡胺组第90天mRS 0-1分比例50.8%,高于安慰剂组44.1%(风险差6.79%,P<.001)。

这项多中心、随机、双盲、安慰剂对照、平行组试验纳入3448例急性缺血性卒中患者,年龄18-80岁,症状出现48小时内,病前mRS 0或1分,NIHSS评分4-24分,来自中国100个中心。患者按1:1随机接受银杏二萜内酯葡胺或安慰剂,每日一次静脉输注,症状出现后48小时内给药并持续14天,治疗期间不允许溶栓和取栓。主要终点第90天mRS 0或1分比例在银杏二萜内酯葡胺组为50.8%,安慰剂组为44.1%(风险差6.79%,95%CI 3.46%-10.10%;OR 1.31,95%CI 1.15-1.50;RR 1.15,95%CI 1.08-1.24;P<.001)。不良事件两组相当(17.6% vs 17.3%,P=.83)。

要点

  • 银杏二萜内酯葡胺组第90天mRS 0或1分比例50.8%(877/1725),安慰剂组44.1%(759/1723),风险差6.79%(95%CI 3.46%-10.10%),OR 1.31(95%CI 1.15-1.50),RR 1.15(95%CI 1.08-1.24),P<.001。
  • 不良事件发生率银杏二萜内酯葡胺组17.6%(303例)与安慰剂组17.3%(298例)相当,风险差0.27%(95%CI -2.26%至2.80%),OR 1.02(95%CI 0.85-1.21),RR 1.02(95%CI 0.88-1.17),P=.83。
  • 研究方案中银杏二萜内酯葡胺每日一次静脉输注,症状出现后48小时内给药,持续14天,治疗期间不允许溶栓和取栓,该方案不等同于通用推荐。
  • 纳入标准为年龄18-80岁、临床诊断急性缺血性卒中且症状出现48小时内、病前mRS 0或1分、NIHSS评分4-24分。
  • 作者结论认为,在急性缺血性卒中患者中,与安慰剂相比,银杏二萜内酯葡胺提高了第90天达到良好临床结局的患者比例。

适用人群与场景

  • 年龄18-80岁、临床诊断急性缺血性卒中且症状出现48小时内、病前mRS评分0或1分、NIHSS评分4-24分的患者。
  • 研究在中国100个中心开展,治疗期间不允许溶栓和取栓。

诊断标准与关键阈值

  • 病前改良Rankin量表(mRS)评分0或1分。
  • 美国国立卫生研究院卒中量表(NIHSS)评分4-24分。

处置流程与药物剂量

  • 银杏二萜内酯葡胺每日一次静脉输注,症状出现后48小时内给药,持续14天(研究方案,非通用推荐)。
  • 治疗期间不允许溶栓和取栓(研究方案规定)。

研究设计与关键结果

  • 多中心、随机、双盲、安慰剂对照、平行组试验,纳入3448例患者,银杏二萜内酯葡胺组1725例,安慰剂组1723例;中位年龄63岁(IQR 55-71),女性1232例(35.7%)。
  • 主要终点第90天mRS 0或1分:银杏二萜内酯葡胺组877例(50.8%)vs 安慰剂组759例(44.1%),风险差6.79%(95%CI 3.46%-10.10%),OR 1.31(95%CI 1.15-1.50),RR 1.15(95%CI 1.08-1.24),P<.001。
  • 不良事件:银杏二萜内酯葡胺组303例(17.6%)vs 安慰剂组298例(17.3%),风险差0.27%(95%CI -2.26%至2.80%),OR 1.02(95%CI 0.85-1.21),RR 1.02(95%CI 0.88-1.17),P=.83。

证据类型、等级与局限

  • 证据类型:多中心、随机、双盲、安慰剂对照、平行组临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在急性缺血性卒中患者中,与安慰剂相比,银杏二萜内酯葡胺提高了第90天达到良好临床结局(mRS 0或1分)的患者比例。
  • 研究方案中银杏二萜内酯葡胺每日一次静脉输注、症状出现后48小时内给药并持续14天,且治疗期间不允许溶栓和取栓,该方案不等同于通用推荐。
  • 适用人群为年龄18-80岁、症状出现48小时内、病前mRS 0或1分、NIHSS评分4-24分的急性缺血性卒中患者。

指南或共识出处

  • 临床试验注册号:ClinicalTrials.gov NCT02526225。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Ginkgo diterpene lactone meglumine (GDLM) has attracted much attention because of its potential neuroprotective properties in ischemic stroke. The efficacy of GDLM in patients with acute ischemic stroke (AIS) needs to be verified by well-designed randomized clinical trials.

OBJECTIVE: To assess the efficacy and safety of GDLM in patients with AIS.

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial involved 3448 patients who had AIS, were aged 18 to 80 years, had a clinically diagnosed AIS symptom within 48 hours of onset, had a modified Rankin Scale (mRS) score of 0 or 1 prior to onset, and had a National Institutes of Health Stroke Scale score ranging from 4 to 24. The trial took place at 100 centers in China from February 1, 2016, to May 1, 2018. The mRS is a global stroke disability scale with scores ranging from 0 (no symptoms or completely recovered) to 6 (death). The National Institutes of Health Stroke Scale is a tool used by clinicians to quantify impairment caused by stroke (range, 0-42, with higher scores indicating greater severity). Data were analyzed from January 2019 to December 2022.

INTERVENTIONS: Patients were randomized to receive GDLM or placebo once daily via intravenous infusion in a 1:1 ratio. The treatment was dispensed within 48 hours after symptoms and continued for 14 days. Interventions of thrombolysis and thrombectomy were not permitted during the treatment.

MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with an mRS of 0 or 1 on day 90 after randomization. Safety outcomes included adverse events and serious adverse events.

RESULTS: A total of 3448 patients were randomized, with 1725 patients assigned to the GDLM group and 1723 patients assigned to the placebo group. The median (IQR) age of the patients was 63 (55-71) years, and 1232 (35.7%) were women. The primary outcome on day 90 occurred in 877 patients (50.8%) in the GDLM group, and 759 patients (44.1%) in the placebo group (risk difference, 6.79%; 95% CI, 3.46%-10.10%; odds ratio, 1.31; 95% CI, 1.15-1.50; relative risk, 1.15; 95% CI, 1.08-1.24; P < .001). Adverse events occurred relatively equally between the 2 groups (303 [17.6%] vs 298 [17.3%]; risk difference, 0.27%; 95% CI, -2.26% to 2.80%; odds ratio, 1.02; 95% CI, 0.85-1.21; relative risk, 1.02; 95% CI, 0.88-1.17; P = .83).

CONCLUSIONS AND RELEVANCE: Among patients with AIS in this randomized clinical trial, GDLM improved the proportion of patients achieving favorable clinical outcomes at 90 days compared with placebo.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02526225.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Zhang Q, Wang A, Xu Q, et al. Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37578791. doi:10.1001/jamanetworkopen.2023.28828

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。